Recce Pharma (ASX:RCE) has notched modest gains on Tuesday arvo after reporting its R327 anti-infective gel was effective on burn wounds in an in-vivo model.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This content has been prepared as part of a partnership with Recce Pharmaceuticals Ltd and is intended for informational purposes only.
While that might sound left-of-field for a company otherwise focused on bloodborne infections and infections of wounds following amputations due to diabetes, it forms part of a strategy for the company that might yield promising results.
Somewhat unusual to see for a biotech player (as opposed to industrials and materials stocks), Recce is angling to pivot itself towards the U.S. defence market.
Principally, it’s now looking at whether or not R327 can provide superior healing for burn wounds in humans, given that the U.S. Defence ecosystem has, in layman’s terms, called out for public companies to help.
As for the early-stage results, they rely on an in-vivo model (read: animal), and the company reported Tuesday that early-stage evidence shows R327 may be sufficiently applied to burns once daily, as opposed to twice daily, which is the regimen for the leading burn wound drug in hospital settings, the antibiotic soframycin.
Similar to its goals around treating diabetic amputations, the company focused on two of the most common bacteria to be found in burn wounds in clinical settings, a type of staph and another similar bacterium.
However, the company also reported: “Wounds treated with R327G exhibited accelerated contraction, with statistically significant improvements observed… healing outcomes were consistently superior to both the untreated and Soframycin-treated groups.”
More market news
Propped up: Oz likely to get commodity supports, but don’t expect Trumpian flair
Before the call: RBA’s inflation trick: Is the number lying to us?
“These results further validate the therapeutic potential of R327G as a topical treatment for infected wounds, including burns, and support its development under the Company’s ongoing collaboration with the U.S. Department of Defence,” RCE added.
RCE last traded at 42cps.
Join the discussion: See what HotCopper users are saying about Recce Pharmaceuticals Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.